Cerus Corporation closes new debt facility of up to $110M with MidCap Financial
What's the deal? Cerus CorporationDealroom has a profile for this one. Try Dealroom →, a blood safety technology company, has closed a new debt facility with MidCap FinancialDealroom has a profile for this one. Try Dealroom → providing up to $110M. The facility includes a five-year term loan and an asset-backed revolving loan, replacing the company's existing $65M term loan with MidCap.
The deal is expected to save Cerus up to $3.5M in annual cash interest expense, thanks to lower borrowing costs and an approximately $30M reduction in outstanding term loan balance.
An initial $35M tranche was funded at closing, with up to $30M more available in $5M increments over the term. Cerus also secured a new five-year revolving loan of up to $45M with improved terms and increased capacity.
Why now? Cerus is positioning itself for growth as it expands its global commercial business. The company's INTERCEPT Blood System for platelets and plasma holds both CE mark and FDA approval — the only pathogen reduction system with both. It also has a red blood cell system under regulatory review in Europe and in late-stage US clinical development.
Refinancing now locks in lower borrowing costs and defers term loan amortisation for 48 months, giving the company breathing room to invest in commercialisation and R&D.
What could go wrong? Cerus still faces execution risk. Regulatory approvals for its red blood cell system are not guaranteed, and the company must convert its growing product portfolio into sustained revenue. Taking on a larger overall facility — even at better terms — adds leverage that could weigh on the balance sheet if growth stalls.
The signal: Cerus, categorised as a late-growth stage company on Dealroom, is following a playbook increasingly common among medtech firms that have regulatory-approved products but are still scaling to profitability: refinancing existing debt on softer terms rather than raising dilutive equity. The involvement of MidCap Financial, a middle-market specialty lender, underscores continued appetite from non-bank credit providers to back life sciences companies with commercial traction but long reinvestment cycles.
Read more: MarketScreener
